PharmX Technologies Ltd (ASX:PHX)

Half Year 2025 Pharmx Technologies Ltd Earnings Call Transcript

Feb 18, 2025 / 11:00 PM GMT

Release Date Price: A$0.083

Transcript

Key Points

Positve

PharmX Technologies Ltd (ASX:PHX) reported a 17% increase in revenue year-on-year, showcasing strong financial performance.
The company has expanded its market coverage to over 99% of pharmacies in New Zealand through a new agreement with Tonic, enhancing its regional presence.
PharmX Technologies Ltd has launched a new analytics platform, providing data-driven insights and creating a new revenue stream.
The company has successfully completed the early termination of the revenue share agreement with Alchemy, allowing for full ownership and investment in marketplace growth.
PharmX Technologies Ltd maintains a strong cash balance, enabling continued investment in growth initiatives and technology upgrades.

Negative

Operating costs have increased due to investments in people and technology, impacting overall profitability.
The company faces competition from other players like Direto, which have higher revenues, posing a challenge to market dominance.
PharmX Technologies Ltd's cash position decreased significantly due to a nearly $10 million payment to settle a legal matter with Fred IT.
There is a lack of detailed revenue breakdown across different platforms, which may limit transparency for investors.
The company anticipates short-term cost increases as it continues to invest in growth and technology, potentially affecting near-term profitability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHX.AX - Pharmx Technologies Ltd
Half Year 2025 Pharmx Technologies Ltd Earnings Call
Feb 18, 2025 / 11:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone. Right, okay, we're going to get moving today. Morning. My name is Tom Culver. I'm the CEO of PAmex, and here I have John Newbury, who is a non-executive director. He, as you may know, has previously been our acting CFO in the business. Now, Zoe, our CFO is back from maternity leave. John will be, remaining in the business as Chief Operating Officer. Today he'll go through the financials for consistency with our previous reporting. And so John will be speaking a little bit later on.

A little bit of housekeeping. Can I please ask everyone to please use the Q&A, so that is down at the bottom of your screen. There is an option to put in questions, which we will address at the end. We have a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.